Humana Inc. (NYSE:HUM) Holdings Lowered by Federated Hermes Inc.

Federated Hermes Inc. trimmed its stake in shares of Humana Inc. (NYSE:HUM) by 5.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 165,747 shares of the insurance provider’s stock after selling 9,727 shares during the quarter. Federated Hermes Inc.’s holdings in Humana were worth $75,881,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Wright Investors Service Inc. bought a new stake in shares of Humana during the 4th quarter worth about $494,000. Livforsakringsbolaget Skandia Omsesidigt grew its stake in shares of Humana by 2.9% in the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 4,427 shares of the insurance provider’s stock worth $2,029,000 after purchasing an additional 124 shares during the last quarter. Daiwa Securities Group Inc. grew its stake in shares of Humana by 25.5% in the 4th quarter. Daiwa Securities Group Inc. now owns 17,021 shares of the insurance provider’s stock worth $7,792,000 after purchasing an additional 3,458 shares during the last quarter. Rakuten Securities Inc. acquired a new position in shares of Humana in the 4th quarter worth approximately $25,000. Finally, Tyche Wealth Partners LLC acquired a new position in shares of Humana in the 4th quarter worth approximately $271,000. 92.38% of the stock is currently owned by institutional investors.

Humana Price Performance

Shares of Humana stock opened at $324.83 on Friday. The firm has a fifty day simple moving average of $343.55 and a 200-day simple moving average of $425.01. The company has a current ratio of 1.59, a quick ratio of 1.59 and a debt-to-equity ratio of 0.63. Humana Inc. has a 1-year low of $299.23 and a 1-year high of $541.21. The stock has a market capitalization of $39.19 billion, a price-to-earnings ratio of 16.39, a PEG ratio of 1.90 and a beta of 0.45.

Humana (NYSE:HUM) last announced its earnings results on Thursday, January 25th. The insurance provider reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.87). Humana had a return on equity of 19.44% and a net margin of 2.34%. The company had revenue of $26.46 billion for the quarter, compared to the consensus estimate of $25.47 billion. During the same period last year, the firm posted $1.62 EPS. The company’s revenue was up 17.9% compared to the same quarter last year. On average, sell-side analysts expect that Humana Inc. will post 16.06 earnings per share for the current year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.09%. Humana’s dividend payout ratio (DPR) is presently 17.86%.

Insider Buying and Selling at Humana

In other news, Director Jorge S. Mesquita bought 545 shares of the stock in a transaction dated Tuesday, February 20th. The shares were acquired at an average price of $367.09 per share, with a total value of $200,064.05. Following the acquisition, the director now owns 2,578 shares in the company, valued at $946,358.02. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.32% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on HUM. The Goldman Sachs Group dropped their target price on shares of Humana from $450.00 to $385.00 and set a “buy” rating on the stock in a research report on Wednesday, April 3rd. UBS Group reissued a “neutral” rating and issued a $370.00 target price (down from $530.00) on shares of Humana in a research report on Friday, January 26th. StockNews.com downgraded shares of Humana from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 26th. Cantor Fitzgerald reissued a “neutral” rating and issued a $391.00 target price on shares of Humana in a research report on Wednesday, April 10th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Humana from a “buy” rating to a “hold” rating and dropped their target price for the stock from $595.00 to $360.00 in a research report on Thursday, January 25th. Eleven analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, Humana currently has an average rating of “Hold” and an average price target of $465.42.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.